Guest Open Access Plus | Free Content | About | Sign in | New Users: Sign up | Mark List  

Current Pharmaceutical Design

Volume 16 Issue 14
ISSN: 1381-6128
eISSN: 1873-4286

 

   All Titles

  Clinical PET Imaging of Insulinoma and Beta-Cell Hyperplasia
  pp.1550-1560 (11) Authors: S. Kauhanen, M. Seppanen, H. Minn, P. Nuutila
 
 
      Abstract

Persistent hyperinsulinemic hypoglycemia (PHH) is caused by solitary benign insulinoma or hyperplasia of pancreatic beta cells. In infants, PHH is caused by functionally defective hyperplastic beta cells, which are either diffusely or focally distributed in the pancreas. In adults, insulinoma is the most common cause of PHH, but recently, an increasing number of beta-cell hyperplasias has been reported among adults. The cause of adult beta-cell hyperplasia is not known. Whether the increased use of bariatric surgery in the treatment of severe obesity plays a role here is under investigation. Accurate localization of disease focus in both insulinoma and focal beta-cell hyperplasia provides an important support for surgery, especially as the use of laparoscopic surgery has increased. Conventional imaging of these challenging pancreatic lesions has evolved during recent years, but current imaging methods still lack sufficient sensitivity or are invasive. In most pancreatic neuroendocrine tumors (NETs), the usefulness of positron emission tomography (PET) with fluorine-labeled fluorodeoxyglucose ([18F]FDG) for lesion detection is limited because of the low glucose turnover of these tumors. Based on the capacity of pancreatic beta cells to take up and decarboxylate amine precursors, several investigators have studied patients with pancreatic NETs using aminoacid precursors, such as [18F]dihydroxyphenylalanine (DOPA) and [11C]hydroxytryptophan (5-HTP), in an attempt to increase the sensitivity of PET scanning. Another characteristic of NETs is the expression of somatostatin receptors, and thus encouraging studies with somatostatin receptor imaging with [18Ga]-labeled somatostatin analogs have emerged as a new interesting imaging tool for the diagnosis of pancreatic NETs. This article provides an overview of our experiences and the current literature on PET imaging in patients with PHH caused by insulinoma or beta-cell hyperplasia.

 
  Keywords: Beta-cell hyperplasia, nesidioblastosis, insulinoma, PET, dihydroxyphenylalanine
  Affiliation: Turku PET Centre and Department of Medicine, University of Turku, P.O. Box 52, FI-20521 Turku, Finland.
 
  Key: New Content Free Content Open Access Plus Subscribed Content

Bentham Science Publishers
www.benthamscience.com

 

  Copyright © 1994 - 2014   Bentham Science Publishers